These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 12876900)

  • 1. Forecasting the future of HIV epidemics: the impact of antiretroviral therapies & imperfect vaccines.
    Blower S; Schwartz EJ; Mills J
    AIDS Rev; 2003; 5(2):113-25. PubMed ID: 12876900
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential impact of tuberculosis vaccines as epidemic control agents.
    Lietman T; Blower SM
    Clin Infect Dis; 2000 Jun; 30 Suppl 3():S316-22. PubMed ID: 10875909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in the transmission dynamics of the HIV epidemic after the wide-scale use of antiretroviral therapy could explain increases in sexually transmitted infections: results from mathematical models.
    Boily MC; Bastos FI; Desai K; Mâsse B
    Sex Transm Dis; 2004 Feb; 31(2):100-13. PubMed ID: 14743073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of primate models for AIDS.
    Haigwood NL
    AIDS Rev; 2004; 6(4):187-98. PubMed ID: 15700617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population effects of preventive and therapeutic HIV vaccines in early- and late-stage epidemics.
    Owens DK; Edwards DM; Shachter RD
    AIDS; 1998 Jun; 12(9):1057-66. PubMed ID: 9662203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination against drug resistance in HIV infection.
    Boberg A; Isaguliants M
    Expert Rev Vaccines; 2008 Feb; 7(1):131-45. PubMed ID: 18251699
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic vaccination against HIV: current progress and future possibilities.
    Puls RL; Emery S
    Clin Sci (Lond); 2006 Jan; 110(1):59-71. PubMed ID: 16336205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theoretical assessment of public health impact of imperfect prophylactic HIV-1 vaccines with therapeutic benefits.
    Elbasha EH; Gumel AB
    Bull Math Biol; 2006 Apr; 68(3):577-614. PubMed ID: 16794946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mathematical study of a staged-progression HIV model with imperfect vaccine.
    Gumel AB; McCluskey CC; van den Driessche P
    Bull Math Biol; 2006 Nov; 68(8):2105-28. PubMed ID: 16868850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy.
    Bezemer D; de Wolf F; Boerlijst MC; van Sighem A; Hollingsworth TD; Prins M; Geskus RB; Gras L; Coutinho RA; Fraser C
    AIDS; 2008 May; 22(9):1071-7. PubMed ID: 18520351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of imperfect vaccines on the evolution of HIV virulence.
    Massad E; Coutinho FA; Burattini MN; Lopez LF; Struchiner CJ
    Med Hypotheses; 2006; 66(5):907-11. PubMed ID: 16442745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the population level effects of an HIV-1 vaccine in an era of highly active antiretroviral therapy.
    Rida W; Sandberg S
    Bull Math Biol; 2009 Apr; 71(3):648-80. PubMed ID: 19214640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decrease in drug resistance levels of the HIV epidemic can be bad news.
    Sánchez MS; Grant RM; Porco TC; Gross KL; Getz WM
    Bull Math Biol; 2005 Jul; 67(4):761-82. PubMed ID: 15893552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial suggests vaccines could aid HIV therapy.
    Check E
    Nature; 2003 Apr; 422(6933):650. PubMed ID: 12700722
    [No Abstract]   [Full Text] [Related]  

  • 15. New strategies to combat HIV: augmenting antiviral immunity.
    Smith KA; Boyle BA
    AIDS Read; 2003 Aug; 13(8):365-9, 382. PubMed ID: 14524321
    [No Abstract]   [Full Text] [Related]  

  • 16. Potential public health impact of imperfect HIV type 1 vaccines.
    Anderson R; Hanson M
    J Infect Dis; 2005 Feb; 191 Suppl 1():S85-96. PubMed ID: 15627235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of antiretroviral immunotherapy trials with potentially non-normal and incomplete longitudinal data.
    Mogg R; Mehrotra DV
    Stat Med; 2007 Feb; 26(3):484-97. PubMed ID: 16625520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global HIV cohort studies among injecting drug users and future vaccine trials.
    Woratanarat T
    J Med Assoc Thai; 2006 Jul; 89(7):1064-79. PubMed ID: 16881444
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of vaccine research and development: the human immunodeficiency virus (HIV).
    Girard MP; Osmanov SK; Kieny MP
    Vaccine; 2006 May; 24(19):4062-81. PubMed ID: 16530298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling the potential public health impact of imperfect HIV vaccines.
    Blower S
    J Infect Dis; 2005 Oct; 192(8):1494-5; author reply 1495-6. PubMed ID: 16170769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.